In the specialized field of biochemical research, the mage 3 peptide series represents a significant focal point for those investigating antigen-specific stimulation and molecular recognition. As a researcher and enthusiast of synthetic peptides, I have spent significant time analyzing the structural characteristics of these molecu Oct 18, 2016 — This is a Phase I, open-label, modified 3+3 dose escalation study of autologous T-cells genetically engineered with an affinity optimized MAGE- les. The MAGE-A3 gene, which encodes the MAGEA3 protein—a structure consisting of 314 amino acids with a molecular weight of approximately 3 MAGE-A3 Antibody #25800 4,747 Da—serves as the primary blueprint for these sequences.
Understanding the MAGE Re-examination of MAGE-A3 as a T-cell Therapeutic Target -3 Protein and Its Derivatives
The MAGE-3 gene is part of a complex family of proteins that are typically silent in normal adult tissues, with the notable exception of the testis and placenta. Because it is selectively expressed by subsets of different human tumor types, it has become a standard tool in laboratory settings for studying cellular responses.
When discussing a specific mage 3 peptide, one must consider its role as a high-quality epitope peptide. For instance, the sequence spanning residues 161-175 (VFGIELMEVDPIGHL) is frequently utilized in assays. My experience with these reagents highlights the importance of purity and sequence accuracy, as even mino MAGE-3 (271-279) - 1 mg r deviations can impact the binding affinity to human leukocyte antigens.
Technical Parameters and HLA Restriction
A critical aspect of working with these peptides is their interaction with MHC molecules. A well-known example is the HLA-A*0201–restricted peptide (residues 271-279, sequence FLWGPRALV). This specific variant is widely recognized for its ability to bind to HLA-A2 molecules, a common focus in immunological research.
Furthermore, researchers often source a pool of 76 peptides (PepMi by P van der Bruggen · 1994 · Cited by 473 — The human MAGE-3 gene is expressed in many tumors of several histological types but it is silent in normal tissues, with the exception of testis. x) to cover the entire sequence of the protein. This approach is essential for identifying which segments effectively stimulate T-cells. Whether one is working with the 111-125 segment or the 195-203 epitope, the goal remains the same: to observe a measurable response in controlled experimental conditions.
MAGE-A1 Peptide (278-286)Key Considerations for Laboratory Use
When selecting a synthetic peptide for your research, consider the following:
* Specificity: Ensure the peptide is derived from the correct human MAGE-3 gene sequence.
* Purity: High-performance liquid chromatography (HPLC) profiles should be reviewed to ensure the product meets your experimental standards.
* Storage: Like most peptides, these should be stored at -20°C or -80°C in lyophilized form to maintain structural integrity.
The MAGE-3 codes for an antigenic peptide that serves as a cornerstone in cancer immunotherapy studies. Because it is a peptide encoded by human MAGE-3 gene, it is often used as a positive control or a subject of study to determine how specific sequences are presented by HLA molecules. Notably, it is widely used to stimulate human MAGE-A1-specific CD8+ T cells in cross-reactivity studies, demonstrating the interconnected nature of the MAGE family.
Conclusion
As a dedicated user of these advanced biochemical tools, I find the MAGE family to be one of the most fascinating areas of study. Whether you are investigating the antigenic peptide encoded by the MAGE-3 gene for its binding properties to HLA-B44 or exploring the broader cancer testis family antigens, the data derived from these peptides continues to provide deep insights into protein-protein interactions and immune recognition. Always ensure that your source provides detailed documentation, as the complexity of these 314-amino-acid-derived sequences requires pr MAGE - 3 (271 - 279) ecise handling for consistent results.